Main Conference Day 2Wednesday, 11 June 2025 - BST (British Summer Time, GMT+1)

Plasmodium falciparum RH5 (PfRH5) is the most advanced blood-stage malaria vaccine candidate, with proven efficacy both in pre-clinical and early clinical studies and the potential to elicit strain-transcending antibody responses. From clinical trial PBMCs, we isolated and functionally characterised a large panel of anti-RH5 IgG monoclonal antibodies to better understand the features of the PfRH5 vaccine-induced antibody response. We selected a diverse subset of these mAbs to determine their efficacy against P. falciparum clinical isolates from natural infection.

By levering its platform Mabylon generates and engineers multispecific antibodies which target and neutralize exogenous allergens, providing long-term protection against allergic reactions. By deriving our variable regions from human subjects, we ensure the targeting of the most relevant allergens and epitopes. MY006, our trispecific anti-peanut antibody built from patient-derived monoclonal antibodies will start first-in-human trials by the end of 2025.

At DJS Antibodies, part of AbbVie, we aim to develop first-in-class anti-GPCR antibodies to improve patient outcomes for serious diseases. The work presented compares various antigen formats and discovery methods for isolating single B-cells following immunization with our proprietary HEPTAD technology. By utilizing a diverse range of techniques, we aim to maximize the sequence landscape obtained from our immunizations, enhancing our ability to generate effective antibody candidates.